Stocktoria
C4 Therapeutics, Inc. CCCC
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-02
C4 Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -320.5% | -336.1% | -669.8% | -416.6% | -179.4% |
| Net margin | -292.1% | -296.0% | -638.3% | -412.2% | -183.2% |
| FCF margin | -276.2% | -183.6% | -523.0% | -358.4% | -192.7% |
| Return on assets | -29.2% | -30.1% | -35.2% | -29.8% | -16.6% |
| Return on equity | -40.9% | -48.8% | -53.8% | -44.3% | -21.5% |
| Debt / equity | — | — | 0.00× | 0.04× | 0.03× |
| Current ratio | 7.81 | 5.71 | 6.34 | 6.46 | 6.36 |
| Revenue growth | 1.0% | 71.4% | -33.3% | -32.1% | — |
Source: SEC EDGAR filings · CIK 0001662579 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.